Verrica Pharmaceuticals (NASDAQ:VRCA) Stock Price Up 0% - What's Next?

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) shares traded up 0% during mid-day trading on Monday . The stock traded as high as $0.63 and last traded at $0.61. 94,422 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 585,165 shares. The stock had previously closed at $0.61.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on VRCA shares. HC Wainwright reiterated a "neutral" rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, April 8th. Wall Street Zen upgraded shares of Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, Needham & Company LLC restated a "hold" rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, May 14th. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Verrica Pharmaceuticals presently has a consensus rating of "Hold" and a consensus target price of $8.00.

Verrica Pharmaceuticals Stock Performance

The stock's 50 day simple moving average is $0.53 and its 200 day simple moving average is $0.65. The firm has a market cap of $57.63 million, a P/E ratio of -0.34 and a beta of 1.75.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.04. The company had revenue of $3.44 million for the quarter, compared to analyst estimates of $2.53 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. As a group, analysts forecast that Verrica Pharmaceuticals Inc. will post -1.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Invesco Ltd. purchased a new stake in Verrica Pharmaceuticals in the 4th quarter valued at $32,000. AQR Capital Management LLC boosted its holdings in Verrica Pharmaceuticals by 306.7% during the first quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock worth $26,000 after purchasing an additional 44,275 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Verrica Pharmaceuticals by 127.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company's stock worth $44,000 after purchasing an additional 55,852 shares in the last quarter. Kovitz Investment Group Partners LLC bought a new stake in Verrica Pharmaceuticals in the 1st quarter worth about $45,000. Finally, Goldman Sachs Group Inc. increased its stake in Verrica Pharmaceuticals by 23.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company's stock valued at $61,000 after buying an additional 26,308 shares during the last quarter. Institutional investors own 42.45% of the company's stock.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.